Advertisement
YOU ARE HERE: LAT HomeCollectionsNeotherapeutics Inc
IN THE NEWS

Neotherapeutics Inc

FEATURED ARTICLES
BUSINESS
July 3, 1997 | Barbara Marsh
NeoTherapeutics Inc., flush with millions after an initial public offering last year, is bursting with growth. "The offering allowed us to scale everything up," said Michelle Glasky, the company's director of scientific affairs. The tiny Irvine drug development company was founded 10 years ago by her father, Alvin J. Glasky, a scientist, who is also its chief executive and top inventor. A year ago, it employed four and worked out of a small office.
ARTICLES BY DATE
BUSINESS
April 30, 2002 | Bloomberg News
NeoTherapeutics Inc. shares fell 64% as the company said its most advanced experimental product, the Neotrofin medication for Alzheimer's disease, didn't work as expected in human testing. The Irvine firm's stock fell $1.40 to 80 cents on Nasdaq. The shares had fallen 40% this year. Patients on Neotrofin didn't show a statistically significant benefit compared with those given a placebo treatment in a 12-week study.
Advertisement
BUSINESS
May 19, 2000
The Irvine company, which researches and develops treatments for neurological diseases, posted a first-quarter net loss of $9.3 million, or $1.02 a share, compared with a net loss of $4.4 million, or 71 cents a share, a year ago. No revenue was reported.
NEWS
April 30, 2002 | From Bloomberg News
NeoTherapeutics Inc. shares fell 64% as the company said its most advanced experimental product, the Neotrofin medication for Alzheimer's disease, didn't work as expected in human testing. The Irvine company's stock fell $1.40 to 80 cents on Nasdaq. Before Monday, the shares had fallen 40% this year. Patients on Neotrofin didn't show a statistically significant benefit compared with those given a placebo treatment in a 12-week study.
BUSINESS
August 22, 2000 | Dow Jones
NeoTherapeutics Inc., an Irvine pharmaceuticals company, said Monday that Rajesh C. Shrotriya has been named president, effective Sept. 1. A company spokeswoman said Shrotriya assumes the post from Alvin Glasky, who will remain chief executive, chairman and chief scientific officer. In a news release Monday, the company said Shrotriya was most recently executive vice president and chief scientific officer of SuperGen Inc.
BUSINESS
June 4, 1999 | Bloomberg News
NeoTherapeutics Inc. plans to sell 3.5 million shares of common stock to raise money for trials of its experimental Alzheimer's treatment, Neotrofin, and other drugs in development, according to regulatory documents filed Thursday. The Irvine-based company announced Wednesday that Neotrofin improved brain function in 72% of patients in a clinical trial.
BUSINESS
August 7, 1999
NeoTherapeutics Inc.: The Irvine development-stage biopharmaceutical company reported a net loss of $4.1 million, or 63 cents a share, for the second quarter, compared with a net loss of $2.6 million, or 47 cents a share, for the second quarter of 1998. No revenue was reported.
BUSINESS
November 13, 1999
NeoTherapeutics Inc., an Irvine drug development company, reported a net loss of $5.3 million, or 70 cents a share, for the third quarter, compared with a net loss of $3 million, or 54 cents a share, for the 1998 third quarter. No revenue was recorded.
BUSINESS
March 14, 2001
IAT ReInsurance Syndicate Ltd. increased its stake in NeoTherapeutics Inc. to about 13% by acquiring 1.25 million shares of the Irvine pharmaceutical company and 125 warrants at an exercise price of $5 per share, NeoTherapeutics said. The company said it raised about $5 million through the transaction.
BUSINESS
March 21, 2001
Irvine biopharmaceutical company NeoTherapeutics Inc. incurred a net loss of $11.5 million, or 88 cents a share, for the fourth quarter, down from a net loss of $12.2 million, or $1.47 a share, for the 1999 fourth quarter, which included a charge of $2.5 million for a legal settlement. For the year, the company posted a net loss of $46.4 million, or $4.37 a share, compared with a 1999 net loss of $26 million, or $3.68 a share. The development-stage company reported no revenue.
BUSINESS
March 20, 2001 | From Dow Jones Newswires
Investors swept up shares of NeoTherapeutics Inc. on Monday after the Irvine biopharmaceutical company announced a license agreement with Pfizer Inc. worth up to $12 million. NeoTherapeutics, which until now has not generated revenue, will receive an initial payment from Pfizer.
BUSINESS
February 8, 2001 | From Dow Jones Newswires
NeoTherapeutics Inc.'s climbing stock moved up an additional 30% Wednesday, snapped up by investors after the company said it is planning a pivotal study of its drug compound for treating Alzheimer's disease. The Irvine biopharmaceutical company also said this week that a subsidiary received $7 million in new financing. The stock, which rose 15% on Tuesday and 14% on Monday, closed Wednesday at $4.16, up 97 cents a share in Nasdaq trading. A total of 1.
BUSINESS
January 3, 2001 | Dow Jones
NeoTherapeutics Inc. filed a shelf registration statement with the Securities and Exchange Commission to issue up to $50 million of debt securities, stock, depositary shares or warrants. The Irvine biopharmaceutical company said Tuesday the filing allows it "speed and flexibility" when market conditions are attractive. A shelf filing lets the company register securities in advance and sell them from time to time as needed.
BUSINESS
December 19, 2000 | Dow Jones
NeoTherapeutics Inc. said clinical data from a study of its nerve-regeneration drug Neotrofin showed the treatment facilitates brain activity in Alzheimer's disease patients. The Irvine biopharmaceutical company said the study, which treated 19 patients with Neotrofin, resulted in significant improvement in memory, attention and judgment.
BUSINESS
November 30, 2000 | Times Staff and Dow Jones
NeoTherapeutics Inc., an Irvine biopharmaceutical company specializing in nerve regeneration research, said Wednesday that it has expanded its mission by forming a cancer therapy unit. The company said in a press release that it has named Dr. Luigi Lenaz, who has held executive positions at Bristol-Myers Squibb Co. for nearly 20 years, as president of the new unit, called NeoOncoRx.
BUSINESS
November 4, 2000
The Irvine biopharmaceutical incurred a third-quarter net loss of $13.2 million, or $1.27 a share, which included a noncash charge of $1 million from the sale of convertible preferred stock of its NeoGene unit. The net loss for the same period last year was $5.3 million, or 70 cents a share. Revenue was not reported.
Los Angeles Times Articles
|